TY - JOUR AB - Effect of bortezomib on proliferation and apoptosis of myeloma cells by activating Wnt/β‑catenin signaling pathway was investigated. Myeloma cells RPMI‑8226 treated with different concentrations of bortezomib were used as experimental groups, and the untreated cells were used as the control group. The proliferation and apoptosis in all groups of cells were detected, as well as the expression levels of Wnt/β‑catenin signaling pathway‑related proteins, β‑catenin and c‑Myc. The results revealed that bortezomib could inhibit the proliferation of myeloma cells. The apoptotic rates of RPMI‑8226 cells in the groups treated with 20, 50 and 80 nmol/l of bortezomib were 12.08±0.61, 35.97±3.11 and 57.22±5.47%, respectively, which were significantly higher than that in the control group (8.28±0.39%) (P<0.05). The expression levels of β‑catenin and c‑Myc in the experimental groups were significantly lower than those in the control group (P<0.05). Bortezomib can reduce the expression level of Wnt/β‑catenin signaling pathway‑related proteins, β‑catenin and c‑Myc, and may inhibit cell proliferation and accelerate apoptosis by activating the Wnt/β‑catenin signaling pathway. AD - Department of Medical Laboratory Technology, Chuxiong Medical College, Chuxiong, Yunnan 675000, P.R. China School of Nursing, Chuxiong Medical College, Chuxiong, Yunnan 675000, P.R. China Department of Pharmacy, Chuxiong Medical College, Chuxiong, Yunnan 675000, P.R. China AU - Dai,Yanling AU - Guo,Xiaomin AU - Yang,Chunyan DA - 2020/08/01 DO - 10.3892/ol.2020.11678 EP - 1299 IS - 2 JO - Oncol Lett KW - bortezomib signaling pathway myeloma cell prolife­ration cell apoptosis PY - 2020 SN - 1792-1074 1792-1082 SP - 1295 ST - Effect of bortezomib on proliferation and apoptosis of myeloma cells by activating Wnt/β‑catenin signaling pathway T2 - Oncology Letters TI - Effect of bortezomib on proliferation and apoptosis of myeloma cells by activating Wnt/β‑catenin signaling pathway UR - https://doi.org/10.3892/ol.2020.11678 VL - 20 ER -